Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The implications of IDH mutations for cancer development and therapy
Christopher J. Pirozzi, Hai Yan
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 10, pp. 645-661
Closed Access | Times Cited: 247

Showing 26-50 of 247 citing articles:

New drug approvals for 2022: Synthesis and clinical applications
Shuo Yuan, Dandan Shen, Rui Jia, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 6, pp. 2352-2391
Closed Access | Times Cited: 18
Protein Kinase B (PKB/AKT) Protects IDH-Mutated Glioma from Ferroptosis via Nrf2
Yang Liu, Fu-Ju Chou, Fengchao Lang, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 7, pp. 1305-1316
Open Access | Times Cited: 16
Olutasidenib: from bench to bedside
Sangeetha Venugopal, Justin M. Watts
Blood Advances (2023) Vol. 7, Iss. 16, pp. 4358-4365
Open Access | Times Cited: 16
Oncometabolite 2-hydroxyglutarate regulates anti-tumor immunity
Mengyuan Cai, Jianyi Zhao, Qiang Ding, et al.
Heliyon (2024) Vol. 10, Iss. 2, pp. e24454-e24454
Open Access | Times Cited: 7
Scutellarin activates IDH1 to exert antitumor effects in hepatocellular carcinoma progression
Zhao Cui, Caifeng Li, Wei Liu, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 4
Open Access | Times Cited: 7
The Cancer Antioxidant Regulation System in Therapeutic Resistance
Xuanhao Gu, Chunyang Mu, Rujia Zheng, et al.
Antioxidants (2024) Vol. 13, Iss. 7, pp. 778-778
Open Access | Times Cited: 6
Harnessing the evolving CRISPR/Cas9 for precision oncology
Tianye Li, Shuiquan Li, Yue Kang, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 6
Impact of CDKN2A/B Homozygous Deletion on the Prognosis and Biology of IDH-Mutant Glioma
Eric Huang
Biomedicines (2022) Vol. 10, Iss. 2, pp. 246-246
Open Access | Times Cited: 26
Applications of chemical exchange saturation transfer magnetic resonance imaging in identifying genetic markers in gliomas
Shanshan Jiang, Zhibo Wen, Sung Soo Ahn, et al.
NMR in Biomedicine (2022) Vol. 36, Iss. 6
Open Access | Times Cited: 26
Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma
Pavlina Chuntova, Akane Yamamichi, Tiffany Chen, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 5, pp. e004644-e004644
Open Access | Times Cited: 26
The IDH1 inhibitor ivosidenib improved seizures in a patient with drug-resistant epilepsy from IDH1 mutant oligodendroglioma
Anh Huan Vo, Prakash Ambady, David C. Spencer
Epilepsy & Behavior Reports (2022) Vol. 18, pp. 100526-100526
Open Access | Times Cited: 23
IDH1 p.R132H ctDNA and D-2-hydroxyglutarate as CSF biomarkers in patients with IDH-mutant gliomas
Yoko Fujita, Luis Nunez-Rubiano, Antonio Dono, et al.
Journal of Neuro-Oncology (2022) Vol. 159, Iss. 2, pp. 261-270
Open Access | Times Cited: 22
The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer
Yang Liu, Wei Xu, Mingxue Li, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 4, pp. 1438-1466
Open Access | Times Cited: 13
The Role of Mutant IDH Inhibitors in the Treatment of Glioma
Vihang Nakhate, Aleksandra B. Lasica, P. Y. Wen
Current Neurology and Neuroscience Reports (2024)
Closed Access | Times Cited: 5
Isocitrate Dehydrogenase Mutations in Cancer: Mechanisms of Transformation and Metabolic Liability
Kathryn Gunn, Julie-Aurore Losman
Cold Spring Harbor Perspectives in Medicine (2024) Vol. 14, Iss. 5, pp. a041537-a041537
Closed Access | Times Cited: 4
Isocitrate dehydrogenase 2 regulates the proliferation of triple-negative breast cancer through the ferroptosis pathway
Cheng-Wu Zhang, Yuanhong Zhou, Tao Chen, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Altered cancer metabolism and implications for next-generation CAR T-cell therapies
Rishab Ramapriyan, Vivasvan S. Vykunta, Gust Vandecandelaere, et al.
Pharmacology & Therapeutics (2024) Vol. 259, pp. 108667-108667
Closed Access | Times Cited: 4
Oncometabolites in cancer: from cancer cells to the tumor microenvironment
Luoyi Chen, Min Huang
Holistic Integrative Oncology (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 4
NAMPT-targeting PROTAC and nicotinic acid co-administration elicit safe and robust anti-tumor efficacy in NAPRT-deficient pan-cancers
Xiaotong Zhu, Ye Li, Haixia Liu, et al.
Cell chemical biology (2024) Vol. 31, Iss. 6, pp. 1203-1218.e17
Closed Access | Times Cited: 4
Treatment of IDH-mutant glioma in the INDIGO era
Mathew D. Lin, Alexander C.-Y. Tsai, Kalil G. Abdullah, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 4
Advances in Glioblastoma Diagnosis: Integrating Genetics, Noninvasive Sampling, and Advanced Imaging
R. Annie Gough, Randall W. Treffy, Max Krucoff, et al.
Cancers (2025) Vol. 17, Iss. 1, pp. 124-124
Open Access
IDH-mutant gliomas in children and adolescents - from biology to clinical trials
Louise Evans, Sarah Trinder, Andrew Dodgshun, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
Exploring metabolic reprogramming in esophageal cancer: the role of key enzymes in glucose, amino acid, and nucleotide pathways and targeted therapies
Xue-Man Dong, Lin Chen, Yuxin Xu, et al.
Cancer Gene Therapy (2025)
Closed Access
ICAM-1 and IL-10 are associated with cognitive dysfunction using the MoCA test in glioma: findings from the NCI Neuro-Oncology Branch Natural History Study
Kaitlynn Slattery, McKenzie C. Kauss, Dhaivat Raval, et al.
Neuro-Oncology Advances (2025)
Open Access
PepGAT, a chitinase-derived peptide, alters the proteomic profile of colorectal cancer cells and perturbs pathways involved in cancer survival
Pedro F.N. Souza, Elmer Adilson Espino Zelaya, Emerson Lucena da Silva, et al.
International Journal of Biological Macromolecules (2025) Vol. 299, pp. 140204-140204
Closed Access

Scroll to top